Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of LP-168 in Healthy Volunteers
NCT05432713Phase 1Completed
- Sponsor
- Lupeng Pharmaceutical
- Start
- May 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in multiple sclerosis (MS) and Neuromyelitis Optica Spectrum Disorder (NMOSD) comparing LP-168 Tablet with Placebo Tablet (2 arms). Primary endpoints: Number of Participants With Treatment Emergent Adverse Events, Severity of Treatment Emergent Adverse Events and 6 more. Started May 2022; status: completed.
02
Drugs
rocbrutinib
03
Conditions
multiple sclerosis (MS)Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT05432713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05432713.